INTS - NASDAQ
Intensity Therapeutics, Inc.
$1.32
+3.9E+2%Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
At a Glance
Live SnapshotIntensity Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Intensity Therapeutics, Inc. Cash Flow Statement
INTS • NASDAQ
| Intensity Therapeutics, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-16.3M | -10.5M | -7.6M | -7.9M | -6M | -5.4M | |
0.0 | 0.0 | 179K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | -179K | 0.0 | 0.0 | 0.0 | |
3.1M | 1.4M | 1.2M | 719.8K | 555.5K | 561.4K | |
76K | 2.6M | 178.9K | 172.1K | 116.8K | 95.2K | |
-2.1M | -633K | 756.7K | 176.8K | -12K | 306.9K | |
-15.2M | -7.2M | -5.5M | -6.8M | -5.4M | -4.4M | |
INVESTING ACTIVITIES | ||||||
-3.1M | -15.1M | (0.0) | (0.0) | -10.9M | -7.1M | |
9.4M | 9M | 0.0 | 0.0 | 15.5M | 8.8M | |
(6.4M) | -6M | (0.0) | (0.0) | (4.6M) | (1.7M) | |
FINANCING ACTIVITIES | ||||||
3.2M | 22.4M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 230K | 2.3M | 2M | 0.0 | 0.0 | |
-332K | -2.2M | 0.0 | 50K | 25K | 0.0 | |
2.9M | 20.5M | 2.3M | 2.1M | 6.3M | 3.9M | |
CASH FLOW SUMMARY | ||||||
-6M | 7.2M | -3.2M | -4.8M | 5.5M | 1.1M | |
8.6M | 1.3M | 4.5M | 9.3M | 3.8M | 2.7M | |
2.6M | 8.6M | 1.3M | 4.5M | 9.3M | 3.8M | |
-15.2M | -7.2M | -5.5M | -6.8M | -5.4M | -4.4M |
SEC Filings
INTS - Filing history and reports
No SEC filings available for INTS
Related Guides
Continue your INTS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.